Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis
Abstract We aimed to summarize the cancer risk among patients with indication of group I pharmaceuticals as stated in monographs presented by the International Agency for Research on Cancer working groups. Following the PRISMA guidelines, a comprehensive literature search was conducted using the Pub...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-50602-6 |